Related Experiment Video
Updated: Jun 18, 2026
09:52
Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma
Published on: January 25, 2015
13.6K
Managing Metastatic Melanoma in 2022: A Clinical Review
Benjamin Switzer1, Igor Puzanov1, Joseph J Skitzki2
1Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY.
JCO Oncology Practice
|February 8, 2022
Summary
Advances in immunotherapy and targeted treatments have improved outcomes for metastatic melanoma patients. This review details current and future strategies for managing advanced melanoma, including risk stratification and toxicity management.
Area of Science:
- Oncology
- Dermatology
- Immunology
Background:
- Cutaneous melanoma is a lethal skin cancer with rising incidence.
- Metastatic melanoma mortality remains a significant challenge despite treatment advances.
- Recent progress in immunomodulatory and targeted therapies has transformed patient care.
Purpose of the Study:
- To provide a comprehensive overview of historical and future advances in advanced melanoma.
- To discuss the translational and clinical implications of these developments.
- To offer multidisciplinary recommendations for clinicians managing advanced melanoma patients.
Main Methods:
- Literature review of recent advancements in melanoma research and treatment.
- Analysis of immunologic and cancer cell biology contributions.
- Synthesis of multidisciplinary recommendations for clinical practice.
Main Results:
- Immunomodulatory and targeted therapies have significantly improved response and survival rates.
- Advances optimize risk stratification, prognostication, treatment, toxicity management, and surveillance.
- New insights enhance the clinical management of advanced melanoma.
Conclusions:
- Current treatment paradigms for advanced melanoma have been revolutionized by immunotherapy and targeted therapies.
- Multidisciplinary approaches are crucial for effective patient management.
- Future research directions are essential for continued progress in combating metastatic melanoma.
Related Concept Videos
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
01:30Skin Cancer
Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...